ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Medicare Drug Price Negotiation: What ACR Members Need to Know Ahead of Round Three

From the College  |  August 22, 2025

As the program enters its third round of negotiations, ACR members should be aware of several upcoming changes relevant to rheumatology.

Filed under:Legal Updates Tagged with:Medicare Drug Price Negotiation

Key Research in Vasculitis Encapsulated

Philip Seo, MD, MHS  |  August 6, 2025

Summaries of selected research abstracts on the assessment & management of systemic vasculitis from ACR Convergence 2024.

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumVasculitis Tagged with:AAV FocusRheumACR Convergence 2024DADA2eosinophilic granulomatosis with polyangiitis (EGPA)Giant Cell ArteritisGlucocorticoidsgranulomatosis with polyangiitisIgG4 related diseaseinebilizumabInterleukinJAK inhibitormepolizumabupadacitinibVasculitis

JAK Inhibitors 101

Jason Liebowitz, MD, FACR  |  July 28, 2025

Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherGuidanceMeeting Reports Tagged with:EULAR 2025JAK inhibitorsJanus Kinase Inhibitors

Finding the Panacea: The Management of Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  July 16, 2025

In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPsoriatic Arthritis Tagged with:Axial Psoriatic Arthritis (axPsA)EULAR 2025PsAPsA Resource Centerpsoriatic arthritisskin

Highlights from the European Congress of Internal Medicine

Vanessa Caceres  |  July 10, 2025

An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.

Filed under:ConditionsMeeting ReportsOther Rheumatic ConditionsSystemic Lupus Erythematosus Tagged with:abataceptCAR-T cell therapyEuropean Congress of Internal MedicineGiant Cell ArteritisGlucocorticoidsInterstitial Lung DiseaseMethotrexatenintedanibPolymyalgia Rheumaticarituximabserological testingstem cell transplantationSystemic sclerosis

ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting

From the College  |  June 23, 2025

An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:ACR advocacyAMA House of Delegates (HOD)

Biosimilar Update: 2025 Brings More FDA Approvals & Interchangeability

Michele B. Kaufman, PharmD, BCGP  |  June 18, 2025

Here is a brief recap of the latest FDA-approved biosimilar agents, highlighting their reference products and interchangeability.

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBiosimilarsdenosumabFDA approvalinterchangeabilityU.S. Food and Drug Administration (FDA)

Lupus Nephritis: A Brief Review

Keri Losavio  |  May 15, 2025

Among patients with sys­temic lupus erythematosus (SLE), lupus nephritis is one of the more common health problems and a leading cause of mortality. In adults with SLE, as many as five of 10 will develop kidney disease. In children with lupus, eight of 10 will develop kidney disease.1 Lupus nephritis appears to be more prevalent…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lupus nephritis

Pressures Intensify for Rheumatology Researchers

Ruth Jessen Hickman, MD  |  May 12, 2025

Many rheumatology researchers share concerns about the landscape for future opportunities, given recent pressures from the current presidential administration. These may make an already challenging environment even more difficult for academic physicians to successfully navigate. But many in the field will persevere despite obstacles, driven by the need to deepen understanding of these conditions and…

Filed under:Research Rheum Tagged with:Research Funding

Editor's Pick

Incorporating Patient-Reported Outcomes into the Clinic

Katie Robinson  |  May 5, 2025

‘Measuring patient-reported outcomes (PROs) is an important component of high-quality, patient-centered care, but integration of PROs into clinic can be challenging,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘Luckily, tools exist to help us realize this vital aspect of patient care.’ The ACR’s quality measures for care include gauging disease activity and…

Filed under:EMRsPatient PerspectivePractice Support Tagged with:Editor's Pickpatient reported outcomes

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences